Trials / Recruiting
RecruitingNCT07172919
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sotorasib | Sotorasib will be administered orally as a tablet. |
| DRUG | Panitumumab | Panitumumab will be administered as an IV infusion. |
Timeline
- Start date
- 2026-01-02
- Primary completion
- 2028-01-02
- Completion
- 2028-01-02
- First posted
- 2025-09-15
- Last updated
- 2026-04-09
Locations
9 sites across 8 countries: United States, Australia, France, Germany, Italy, Japan, Switzerland, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07172919. Inclusion in this directory is not an endorsement.